Breast Cancer–Related Lymphedema: Comparing Direct Costs of a Prospective Surveillance Model and a Traditional Model of Care
| Autor: | Charles L. McGarvey, Lucinda Pfalzer, Ellen W. Levy, Barbara A. Springer, Jerome Danoff, Peter W. Soballe, Lynn H. Gerber, Nicole L. Stout |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
Referral medicine.medical_treatment MEDLINE Breast Neoplasms Physical Therapy Sports Therapy and Rehabilitation Indirect costs Breast cancer Secondary Prevention medicine Humans Lymphedema Prospective Studies Intensive care medicine Prospective cohort study Physical Therapy Modalities Rehabilitation business.industry Cancer medicine.disease Population Surveillance Disease Progression Physical therapy Female business Perspectives |
| Zdroj: | Physical Therapy. 92:152-163 |
| ISSN: | 1538-6724 0031-9023 |
| DOI: | 10.2522/ptj.20100167 |
| Popis: | Secondary prevention involves monitoring and screening to prevent negative sequelae from chronic diseases such as cancer. Breast cancer treatment sequelae, such as lymphedema, may occur early or late and often negatively affect function. Secondary prevention through prospective physical therapy surveillance aids in early identification and treatment of breast cancer–related lymphedema (BCRL). Early intervention may reduce the need for intensive rehabilitation and may be cost saving. This perspective article compares a prospective surveillance model with a traditional model of impairment-based care and examines direct treatment costs associated with each program. Intervention and supply costs were estimated based on the Medicare 2009 physician fee schedule for 2 groups: (1) a prospective surveillance model group (PSM group) and (2) a traditional model group (TM group). The PSM group comprised all women with breast cancer who were receiving interval prospective surveillance, assuming that one third would develop early-stage BCRL. The prospective surveillance model includes the cost of screening all women plus the cost of intervention for early-stage BCRL. The TM group comprised women referred for BCRL treatment using a traditional model of referral based on late-stage lymphedema. The traditional model cost includes the direct cost of treating patients with advanced-stage lymphedema. The cost to manage early-stage BCRL per patient per year using a prospective surveillance model is $636.19. The cost to manage late-stage BCRL per patient per year using a traditional model is $3,124.92. The prospective surveillance model is emerging as the standard of care in breast cancer treatment and is a potential cost-saving mechanism for BCRL treatment. Further analysis of indirect costs and utility is necessary to assess cost-effectiveness. A shift in the paradigm of physical therapy toward a prospective surveillance model is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|